These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 18319003)

  • 1. Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.
    Gay HA; Cavalieri R; Allison RR; Finley J; Quan WD
    Dermatol Online J; 2007 Oct; 13(4):6. PubMed ID: 18319003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bowel perforation after radiotherapy in a patient receiving sorafenib.
    Peters NA; Richel DJ; Verhoeff JJ; Stalpers LJ
    J Clin Oncol; 2008 May; 26(14):2405-6. PubMed ID: 18467733
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
    Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
    Ruppin S; Protzel C; Klebingat KJ; Hakenberg OW
    Eur Urol; 2009 Apr; 55(4):986-8; quiz 988. PubMed ID: 19004541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
    Xie XD; Piao Y; Liu ZZ
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):714-5. PubMed ID: 20021872
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
    Sciarra A; Autran Gomez AM; Gentilucci A; Parente U; Salciccia S; Gentile V; Di Silverio F
    Eur Urol; 2007 Aug; 52(2):597-9. PubMed ID: 17420088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib-induced palmoplantar hyperkeratosis.
    Lountzis NI; Maroon MS
    J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
    Bellmunt J; Fishman M; Eisen T; Quinn D
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):825-35. PubMed ID: 20553208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
    Ansari J; Fatima A; Chaudhri S; Bhatt RI; Wallace M; James ND
    Onkologie; 2009 Feb; 32(1-2):44-6. PubMed ID: 19209019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.
    Kasibhatla M; Steinberg P; Meyer J; Ernstoff MS; George DJ
    Clin Genitourin Cancer; 2007 Mar; 5(4):291-4. PubMed ID: 17553211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
    Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
    Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
    Kamada P; Dudek AZ
    Cancer Invest; 2010 Jun; 28(5):501-4. PubMed ID: 20014944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous metastasis to face and neck as a sole manifestation of an unsuspected renal cell carcinoma.
    Chauhan A; Ganguly M; Nath P; Chowdhary GS
    Int J Dermatol; 2011 Jan; 50(1):81-4. PubMed ID: 21182508
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
    Bukowski RM
    Oncology (Williston Park); 2006 May; 20(6 Suppl 5):25-8. PubMed ID: 16773842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal cell carcinoma with cutaneous metastases.
    Lim C; Chan R; Regan W
    Australas J Dermatol; 2005 Aug; 46(3):158-60. PubMed ID: 16008646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Painful leg mass.
    Lucas LM
    J Fam Pract; 2012 May; 61(5):287-90. PubMed ID: 22577632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecule of the month. Sorafenib.
    Drug News Perspect; 2006 Mar; 19(2):119. PubMed ID: 16628266
    [No Abstract]   [Full Text] [Related]  

  • 19. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
    Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R
    Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
    [No Abstract]   [Full Text] [Related]  

  • 20. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.